A recent article published in the Journal of Clinical Pathways (JCP) looks at the evolution of four different value assessment frameworks, and how they fit into oncology value assessment.
The authors zero in on the Drug Abacus, the American Society of Clinical Oncology (ASCO) Value Framework, the National Comprehensive Cancer Network Evidence Blocks, and the Institute for Clinical and Economic Review Value Assessment Framework.
“The staggering pace of change in oncology therapeutics is a challenge for stakeholders interested in assessing value,” the authors write. “As discussed here, even a few years’ time is enough to make a value assessment tool obsolete with regular updates.”
To read the article on JCP, click here.